A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

被引：551

作者：

Bekker, PJ

Holloway, DL

Rasmussen, AS

Murphy, R

Martin, SW

Leese, PT

Holmes, GB

Dunstan, CR

DePaoli, AM

机构：

[1] Amgen Inc, Thousand Oaks, CA 91320 USA

[2] Quintiles, Lenexa, KS USA

[3] SFBC Int Inc, Miami, FL USA

[4] ANZAC Res Inst, Concord, NSW, Australia

来源：

JOURNAL OF BONE AND MINERAL RESEARCH | 2004年 / 19卷 / 07期

关键词：

RANKL; osteoprotegerin; osteoporosis; bone resorption; AMG; 162;

D O I：

10.1359/JBMR.040305

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The safety and bone antiresorptive effect of a single subcutaneous dose of AMG 162, a human monoclonal antibody to RANKL, was investigated in 49 postmenopausal women. AMG 162 is a potent antiresorptive agent for diseases such as osteoporosis.

引用

页码：1059 / 1066

页数：8

共 50 条

[11] Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients:: semiquantitative and quantitative analysis
Crotti, TN
Smith, MD
Weedon, H
Ahern, MJ
Findlay, DM
Kraan, M
Tak, PP
Haynes, DR
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (12) : 1047 - 1054
[12] Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
Croucher, PI
Shipman, CM
Lippitt, J
Perry, M
Asosingh, K
Hijzen, A
Brabbs, AC
van Beek, EJR
Holen, I
Skerry, TM
Dunstan, CR
Russell, GR
Van Camp, B
Vanderkerken, K
[J]. BLOOD, 2001, 98 (13) : 3534 - 3540
[13] Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women
Eastell, R
Mallinak, N
Weiss, S
Ettinger, M
Pettinger, M
Cain, D
Flessland, K
Chesnut, C
[J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (03) : 594 - 598
[14] Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL
Emery, JG
McDonnell, P
Burke, MB
Deen, KC
Lyn, S
Silverman, C
Dul, E
Appelbaum, ER
Eichman, C
DiPrinzio, R
Dodds, RA
James, IE
Rosenberg, M
Lee, JC
Young, PR
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (23) : 14363 - 14367
[15] NORMAL AND PATHOLOGICAL REMODELING OF HUMAN TRABECULAR BONE - 3-DIMENSIONAL RECONSTRUCTION OF THE REMODELING SEQUENCE IN NORMALS AND IN METABOLIC BONE-DISEASE
ERIKSEN, EF
[J]. ENDOCRINE REVIEWS, 1986, 7 (04) : 379 - 408
[16] Risedronate reverses bone loss in postmenopausal women with low bone mass: Results from a multinational, double-blind, placebo-controlled trial
Fogelman, I
Ribot, C
Smith, R
Ethgen, D
Sod, E
Reginster, JY
[J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (05) : 1895 - 1900
[17] TETRACYCLINE-BASED HISTOLOGICAL ANALYSIS OF BONE REMODELING
FROST, HM
[J]. CALCIFIED TISSUE RESEARCH, 1969, 3 (03): : 211 - &
[18] Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO
[19] 2-P
[20] Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis - A randomized controlled trial
Harris, ST
Watts, NB
Genant, HK
McKeever, CD
Hangartner, T
Keller, M
Chesnut, CH
Brown, J
Eriksen, EF
Hoseyni, MS
Axelrod, DW
Miller, PD
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (14): : 1344 - 1352

← 1 2 3 4 5 →